$7.42
Insights on Voyager Therapeutics, Inc.
Revenue is up for the last 2 quarters, 4.61M → 90.06M (in $), with an average increase of 94.9% per quarter
Netprofit is up for the last 2 quarters, -25.90M → 56.39M (in $), with an average increase of 145.9% per quarter
In the last 1 year, Novo Nordisk A/s has given 52.5% return, outperforming this stock by 52.8%
In the last 3 years, Novo Nordisk A/s has given 239.5% return, outperforming this stock by 203.1%
2.16%
Downside
Day's Volatility :3.46%
Upside
1.33%
18.33%
Downside
52 Weeks Volatility :57.74%
Upside
48.26%
Period | Voyager Therapeutics, Inc. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -1.2% | 0.5% | 0.0% |
6 Months | 12.77% | 11.7% | 0.0% |
1 Year | -0.27% | 6.2% | 2.2% |
3 Years | 36.4% | 13.5% | -23.0% |
Market Capitalization | 412.7M |
Book Value | $5.37 |
Earnings Per Share (EPS) | 2.97 |
PE Ratio | 2.56 |
PEG Ratio | 0.0 |
Wall Street Target Price | 17.78 |
Profit Margin | 52.93% |
Operating Margin TTM | 60.03% |
Return On Assets TTM | 29.87% |
Return On Equity TTM | 89.61% |
Revenue TTM | 250.0M |
Revenue Per Share TTM | 5.81 |
Quarterly Revenue Growth YOY | -88.8% |
Gross Profit TTM | -19.9M |
EBITDA | 126.5M |
Diluted Eps TTM | 2.97 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.8 |
EPS Estimate Next Year | -1.73 |
EPS Estimate Current Quarter | -0.29 |
EPS Estimate Next Quarter | -0.25 |
What analysts predicted
Upside of 139.62%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 7.6M | ↓ 24.82% |
Net Income | -88.3M | ↑ 24.88% |
Net Profit Margin | -1.2K% | ↓ 461.23% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 104.4M | ↑ 1270.14% |
Net Income | -40.8M | ↓ 53.75% |
Net Profit Margin | -39.11% | ↑ 1119.68% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 171.1M | ↑ 63.93% |
Net Income | 36.7M | ↓ 189.98% |
Net Profit Margin | 21.47% | ↑ 60.58% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 37.4M | ↓ 78.14% |
Net Income | -66.0M | ↓ 279.72% |
Net Profit Margin | -176.49% | ↓ 197.96% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 40.9M | ↑ 9.33% |
Net Income | -46.4M | ↓ 29.72% |
Net Profit Margin | -113.45% | ↑ 63.04% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 250.0M | ↑ 511.16% |
Net Income | 132.3M | ↓ 385.14% |
Net Profit Margin | 52.93% | ↑ 166.38% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 41.1M | ↑ 5670.51% |
Net Income | 17.6M | ↓ 193.41% |
Net Profit Margin | 42.9% | ↑ 2692.9% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | -41.1M | ↓ 200.0% |
Net Income | -23.6M | ↓ 234.06% |
Net Profit Margin | 57.5% | ↑ 14.6% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 150.5M | ↓ 466.25% |
Net Income | 124.0M | ↓ 625.03% |
Net Profit Margin | 82.43% | ↑ 24.93% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 4.9M | ↓ 96.77% |
Net Income | -22.2M | ↓ 117.9% |
Net Profit Margin | -457.61% | ↓ 540.04% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 4.6M | ↓ 4.92% |
Net Income | -25.9M | ↑ 16.63% |
Net Profit Margin | -561.36% | ↓ 103.75% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 90.1M | ↑ 1851.91% |
Net Income | 56.4M | ↓ 317.73% |
Net Profit Margin | 62.62% | ↑ 623.98% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 177.0M | ↓ 4.04% |
Total Liabilities | 130.6M | ↑ 158.96% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 354.8M | ↑ 100.4% |
Total Liabilities | 255.2M | ↑ 95.47% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 261.6M | ↓ 26.26% |
Total Liabilities | 107.3M | ↓ 57.98% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 193.9M | ↓ 25.89% |
Total Liabilities | 98.8M | ↓ 7.89% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 159.4M | ↓ 17.8% |
Total Liabilities | 100.3M | ↑ 1.55% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 351.3M | ↑ 120.44% |
Total Liabilities | 115.0M | ↑ 14.58% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 182.5M | ↓ 3.25% |
Total Liabilities | 102.7M | ↓ 20.14% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 159.4M | ↓ 12.67% |
Total Liabilities | 100.3M | ↓ 2.26% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 336.3M | ↑ 111.03% |
Total Liabilities | 119.3M | ↑ 18.93% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 315.5M | ↓ 6.17% |
Total Liabilities | 116.5M | ↓ 2.37% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 294.7M | ↓ 6.62% |
Total Liabilities | 118.4M | ↑ 1.65% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 351.3M | ↑ 19.22% |
Total Liabilities | 115.0M | ↓ 2.93% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -15.9M | ↓ 74.1% |
Investing Cash Flow | 26.5M | ↓ 819.02% |
Financing Cash Flow | 4.7M | ↓ 92.07% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 48.7M | ↓ 406.33% |
Investing Cash Flow | -90.5M | ↓ 441.85% |
Financing Cash Flow | 81.0M | ↑ 1605.5% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -96.7M | ↓ 298.73% |
Investing Cash Flow | 113.0M | ↓ 224.89% |
Financing Cash Flow | 3.2M | ↓ 96.09% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -53.5M | ↓ 44.66% |
Investing Cash Flow | 65.9M | ↓ 41.67% |
Financing Cash Flow | 612.0K | ↓ 80.65% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -12.5M | ↓ 76.63% |
Investing Cash Flow | -7.3M | ↓ 111.14% |
Financing Cash Flow | 1.1M | ↑ 81.37% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -16.2M | ↓ 12.33% |
Investing Cash Flow | 34.7M | ↓ 196.1% |
Financing Cash Flow | 15.0K | ↓ 98.14% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -12.2M | ↓ 24.45% |
Investing Cash Flow | 14.1M | ↓ 59.49% |
Financing Cash Flow | 276.0K | ↑ 1740.0% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 123.6M | ↓ 1109.19% |
Investing Cash Flow | 14.5M | ↑ 3.01% |
Financing Cash Flow | 31.3M | ↑ 11242.75% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -835.0K | ↓ 100.68% |
Investing Cash Flow | -24.7M | ↓ 270.2% |
Financing Cash Flow | 1.5M | ↓ 95.06% |
Sell
Neutral
Buy
Voyager Therapeutics, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Voyager Therapeutics, Inc. | -25.95% | 12.77% | -0.27% | 36.4% | -65.28% |
Moderna, Inc. | -1.15% | 39.75% | -18.77% | -40.22% | 304.34% |
Regeneron Pharmaceuticals, Inc. | -7.56% | 12.46% | 14.48% | 77.72% | 159.17% |
Novo Nordisk A/s | -2.8% | 32.13% | 52.48% | 239.51% | 414.16% |
Vertex Pharmaceuticals Incorporated | -4.96% | 10.08% | 23.01% | 83.3% | 130.08% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Voyager Therapeutics, Inc. | 2.56 | 2.56 | 0.0 | -1.8 | 0.9 | 0.3 | NA | 5.37 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 26.04 | 26.04 | 1.46 | 45.0 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 47.43 | 47.43 | 2.4 | 3.35 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.81 | 28.81 | 0.53 | 16.75 | 0.23 | 0.13 | NA | 68.22 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Voyager Therapeutics, Inc. | Buy | $412.7M | -65.28% | 2.56 | 52.93% |
Moderna, Inc. | Buy | $41.7B | 304.34% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $99.5B | 159.17% | 26.04 | 30.14% |
Novo Nordisk A/s | Buy | $562.8B | 414.16% | 47.43 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $103.6B | 130.08% | 28.81 | 36.68% |
Armistice Capital, LLC
EcoR1 Capital, LLC
BlackRock Inc
Vanguard Group Inc
Farallon Capital Management, L.L.C.
T. Rowe Price Associates, Inc.
voyager therapeutics is a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (cns). voyager is committed to advancing the field of aav (adeno-associated virus) gene therapy through innovation and investment in vector optimization and engineering, dosing techniques, as well as process development and production. the company’s initial pipeline is focused on cns diseases in dire need of effective new therapies, including parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (als), and friedreich’s ataxia. founded by scientific and clinical leaders in the fields of aav gene therapy, expressed rna interference and neuroscience, voyager therapeutics was launched in 2014 with funding from leading life sciences investor third rock ventures and is headquartered in cambridge, mass. for more information, please visit www.voyagertherapeutics.com.
Organization | Voyager Therapeutics, Inc. |
Employees | 162 |
CEO | Dr. Alfred W. Sandrock Jr., M.D., Ph.D. |
Industry | Health Technology |